Protagonist Therapeutics, Inc. - Common Stock (PTGX)
55.95
+17.60 (45.89%)
Protagonist Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapeutic solutions for patients suffering from a range of serious diseases
The company employs a unique approach that combines peptide-based drug discovery with advanced technologies to create targeted therapies, aiming to address unmet medical needs in areas such as gastrointestinal conditions, inflammatory diseases, and oncology. With a commitment to scientific rigor and collaboration, Protagonist is advancing its pipeline of drug candidates through clinical trials, striving to bring new treatments to market that can significantly improve patient outcomes.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety results, earning Protagonist $25 million.
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential.
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated.
